Sign In
Buy IVVD
$1.10
-0.0400 (-3.51%)
At Close: Jun 03, 2026
WALTHAM, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced its
Invivyd to Host Conference Call Discussing First Quarter 2024 Financial Results and Business Highlights
05:13pm, Thursday, 02'nd May 2024
WALTHAM, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that
Invivyd Announces $20 Million to $25 Million Improvement in Projected 2024 Year-End Cash Position
07:30am, Tuesday, 30'th Apr 2024
WALTHAM, Mass., April 30, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to protection from serious viral infectious diseases, today announced that followin
Product-specific Q Code (Q0224) facilitates product reimbursement for PEMGARDA; corresponding M Code (M0224) defines reimbursement for product administration Reimbursement through Medicare/Medicaid re
Invivyd Announces CEO Transition
07:30am, Friday, 12'th Apr 2024
WALTHAM, Mass., April 12, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announ
Invivyd Provides PEMGARDA™ Launch Update and Announces 2024 Net Product Revenue Guidance in the Range of $150 Million to $200 Million
04:01pm, Thursday, 04'th Apr 2024
WALTHAM, Mass., April 04, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announ
Invivyd Reports Full Year 2023 Financial Results and Recent Business Highlights
07:00am, Thursday, 28'th Mar 2024
WALTHAM, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announ
Invivyd Announces Interim Exploratory Data on VYD222 from Ongoing CANOPY Clinical Trial
03:28pm, Friday, 22'nd Mar 2024
WALTHAM, Mass., March 22, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announ
WALTHAM, Mass., March 22, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announ
Invivyd to Participate at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
04:02pm, Monday, 05'th Feb 2024
WALTHAM, Mass., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announc
3 Groundbreaking Biotech Stocks to Invest in Now
12:35pm, Monday, 29'th Jan 2024
Biotechnology companies are intriguing investment vehicles because they are part of a pretty speculative industry that allows investors to grow their investments rapidly — if they pick a company bef
All You Need to Know About Invivyd, Inc. (IVVD) Rating Upgrade to Strong Buy
01:32pm, Friday, 12'th Jan 2024
Invivyd, Inc. (IVVD) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Invivyd Stock More Than Doubled Last Week. Is It Too Late to Buy?
05:29am, Saturday, 23'rd Dec 2023
Invivyd is developing an experimental antibody treatment to prevent COVID-19 in immunocompromised patients. An estimated 9 million immunocompromised patients in the U.S. don't respond strongly enough
Invivyd (IVVD) Surges on Positive Data From COVID-19 Study
01:32pm, Tuesday, 19'th Dec 2023
Invivyd (IVVD) reports positive initial data from the phase III CANOPY study on VYD222 for the prevention of symptomatic COVID-19. Stock shoots up on the news.
VYD222 produced high serum virus neutralizing antibody titer levels in immunocompromised participants Data supportive of an immunobridging approach to the EVADE study of adintrevimab Overall favorable
